Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Erasca, Inc. (ERAS)

$19.11 -1.19% NASDAQ: ERAS · 15-min delayed
  • SAN DIEGO, California
  • Public · NASDAQ: ERAS
  • 103 employees
$3.7BMarket cap
-$124.5MNet income
103Employees
ERASNASDAQ
2021IPO

About Erasca, Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Net income
-$124.5M
Total assets
$396.2M
Market cap
$3.7B

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2025

Financial statements

Income statement

Revenue
$0
Operating expenses
$140.9M
Operating income
-$140.9M
Income tax
$0
Net income
-$124.5M
EPS (basic)
$-0.44
EPS (diluted)
$-0.44

Balance sheet

Total assets
$396.2M
Current assets
$286.2M
Total liabilities
$71.0M
Current liabilities
$28.5M
Shareholders’ equity
$325.2M

Cash flow

Operating cash flow
-$95.5M
Investing cash flow
$100.4M
Financing cash flow
$1.1M
Net cash flow
$6.1M

Statements via Polygon.io (SEC filings)

NASDAQ: ERAS
$19.11 -1.19%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$1.26 $22.47

52-week range

Market cap
$3.7B
EPS (diluted)
$-0.44
Shares outstanding
194.8M
Open
Day range
Prev close
Volume
IPO date
Jul 16, 2021

Erasca, Inc. (ERAS) Stock Price

  • Reported a net loss of $124.5M.
  • Trading 15% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Erasca, Inc..

Write a review
Newsroom

News about Erasca, Inc.

News & sentiment via Polygon.io

FAQ

Erasca, Inc.: frequently asked questions

Is Erasca, Inc. an American company?

Erasca, Inc. is a US-based company headquartered in San Diego, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Erasca, Inc. headquartered?

Erasca, Inc. is headquartered in San Diego, California, United States.

Is Erasca, Inc. publicly traded?

Yes — Erasca, Inc. is a publicly traded company. Its stock trades under the ticker symbol ERAS on the NASDAQ.

What does Erasca, Inc. do?

Erasca, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →